Researchers evaluated the efficacy and safety of icotrokinra for treating plaque psoriasis affecting the scalp, genital, and/or hand/foot areas.

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra (JNJ-2113) achieved significantly higher skin clearance at 16 ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

Icotrokinra: Promising Results in Ulcerative Colitis and Psoriasis Protagonist’s partnership with Janssen, a Johnson & Johnson company, has yielded positive results for icotrokinra, an oral IL ...

Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with ...

Icotrokinra’s market potential is even more substantial, with some analysts modeling peak sales exceeding $5 billion. This aligns with projections from Protagonist’s partner, Johnson & Johnson ...

Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to J&J Innovative ...

Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to J&J Innovative ...

Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra ...